NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $355,688 | -65.4% | 22,024 | -11.2% | 0.00% | – |
Q2 2023 | $1,029,097 | -45.0% | 24,798 | -20.3% | 0.00% | -100.0% |
Q1 2023 | $1,870,443 | -59.2% | 31,101 | -50.3% | 0.00% | 0.0% |
Q4 2022 | $4,588,042 | +2.9% | 62,550 | +6.5% | 0.00% | 0.0% |
Q3 2022 | $4,460,000 | +6.8% | 58,706 | -2.3% | 0.00% | 0.0% |
Q2 2022 | $4,176,000 | -21.1% | 60,093 | -5.9% | 0.00% | 0.0% |
Q1 2022 | $5,293,000 | +23.3% | 63,885 | +11.7% | 0.00% | 0.0% |
Q4 2021 | $4,294,000 | -55.2% | 57,185 | -30.7% | 0.00% | -50.0% |
Q3 2021 | $9,591,000 | -92.6% | 82,560 | -85.9% | 0.00% | -93.1% |
Q2 2021 | $130,161,000 | -1.1% | 586,787 | -41.1% | 0.03% | -3.3% |
Q1 2021 | $131,604,000 | -33.4% | 995,641 | -12.8% | 0.03% | -37.5% |
Q4 2020 | $197,487,000 | +63.3% | 1,141,281 | +5.0% | 0.05% | +45.5% |
Q3 2020 | $120,942,000 | +50.3% | 1,086,525 | -22.0% | 0.03% | +43.5% |
Q2 2020 | $80,478,000 | +2.2% | 1,392,937 | +15.6% | 0.02% | -14.8% |
Q1 2020 | $78,725,000 | -2.7% | 1,204,524 | +25.4% | 0.03% | +22.7% |
Q4 2019 | $80,948,000 | -8.0% | 960,581 | -18.4% | 0.02% | -12.0% |
Q3 2019 | $88,027,000 | +16.9% | 1,177,144 | -1.1% | 0.02% | +13.6% |
Q2 2019 | $75,281,000 | +48.9% | 1,190,595 | +13.4% | 0.02% | +46.7% |
Q1 2019 | $50,563,000 | +57.7% | 1,049,656 | +9.6% | 0.02% | +36.4% |
Q4 2018 | $32,060,000 | +31.9% | 957,572 | +106.5% | 0.01% | +57.1% |
Q3 2018 | $24,298,000 | +423.2% | 463,729 | +212.6% | 0.01% | +600.0% |
Q2 2018 | $4,644,000 | +112.9% | 148,350 | +48.3% | 0.00% | 0.0% |
Q1 2018 | $2,181,000 | +64.0% | 100,057 | +51.9% | 0.00% | – |
Q4 2017 | $1,330,000 | +1.4% | 65,849 | -0.3% | 0.00% | – |
Q3 2017 | $1,312,000 | +66.3% | 66,058 | +44.8% | 0.00% | – |
Q2 2017 | $789,000 | +171.1% | 45,619 | +26.7% | 0.00% | – |
Q1 2017 | $291,000 | +1.0% | 36,019 | -1.6% | 0.00% | – |
Q4 2016 | $288,000 | +73.5% | 36,619 | +88.4% | 0.00% | – |
Q3 2016 | $166,000 | -98.2% | 19,434 | -97.6% | 0.00% | -100.0% |
Q2 2016 | $9,320,000 | +2609.3% | 798,609 | +3256.5% | 0.00% | – |
Q1 2016 | $344,000 | -29.8% | 23,793 | +8.5% | 0.00% | – |
Q4 2015 | $490,000 | – | 21,932 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |